# US 2021/0341494 A1 · Personalized Medicine Approach for Treating Cognitive Loss

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0341494 A1
- Document ID: US20210341494A1
- Status: Published application
- Kind: A1
- Application number: 17/361,763
- Filed: 2021-06-29
- Published: 2021-11-04
- Earliest claimed: 2013-11-26
- Applicants: University of North Texas Health Science Center at Fort Worth
- Inventors: Sid E. O'Bryant; Leigh A. Johnson
- Web page: https://patentgrep.com/patent/US20210341494A1

## CPC

- G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease}
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C12Q 1/6883: for diseases caused by alterations of genetic material
- G16B 40/00: ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B 40/20: Supervised data analysis
- G16B 40/30: Unsupervised data analysis
- G16H 50/20: for computer-aided diagnosis, e.g. based on medical expert systems
- G16H 50/30: for calculating health indices; for individual health risk assessment
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/158: Expression markers
- G01N 2800/2814: Dementia; Cognitive disorders
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N 2800/60: Complex ways of combining multiple protein biomarkers for diagnosis
- G01N 2800/7095: Inflammation
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA

## Abstract

The present invention includes methods for selecting a therapy for improved cognition as well as prevention of cognitive loss/dysfunction using one or more endophenotypes comprising: obtaining a sample from a subject; measuring biomarkers that differentiate between an inflammatory, a metabolic, a neurotrophic, and a depressive endophenotype; and selecting a course of treatment for the subject based on whether the subject is scored as having a high or a low endophenotype for one or more of the inflammatory, a metabolic, a neurotrophic, and a depressive endophenotypes.

## Claims

### Claim 1

A method for selecting a treatment for improved cognition or prevention of cognitive dysfunction/loss using one or more antidepressant therapies comprising:
determining a depressive endophenotype (DepE) score from a subject; and
if the subject has an increase in the DepE score that is indicative of a depressive endophenotype, selecting a course of treatment for the subject, wherein the treatment is selected from at least one of: an antidepressant, a selective serotonin reuptake inhibitor, a selective serotonin 2C (5-HT2C) antagonist, a serotonin-norepinephrine reuptake inhibitor, or a tricyclic antidepressant.

### Claim 2 (depends on 1)

The method of claim 1, further comprising the step of:
generating a DepE score by determining an increase in one or more of the following: feeling of worse memory problems, feeling downhearted and blue, feeling worthless, frequently feel like crying, and trouble concentrating.

### Claim 3 (depends on 1)

The method of claim 1, wherein elevation of DepE score identifies those eligible for antidepressant therapy for improved cognition or prevention of cognitive loss.

### Claim 4 (depends on 1)

The method of claim 1, wherein the cognitive dysfunction is a disease or condition selected from Alzheimer's Disease, Parkinson's Disease, Down's syndrome, Frontotemporal dementia, Dementia with Lewy Bodies, Multiple sclerosis, traumatic brain injury, depression, schizophrenia, bipolar disease (and other mental illness), diabetes, hypertension, stroke, heart attack, dyslipidemia, other conditions/diseases or aging.

### Claim 5 (depends on 1)

The method of claim 1, wherein the DepE score is analyzed with a receiver operating characteristic (ROC) curve analysis, and an increase in the DepE score is indicative of Alzheimer's Disease.

### Claim 6 (depends on 1)

The method of claim 1, wherein a decrease in the DepE score after treatment is indicative of an improvement in at least one of: immediate memory scores and delayed memory scores.

### Claim 7 (depends on 1)

The method of claim 1, wherein the treatment is initiated before the subject is diagnosed with Alzheimer's Disease.

### Claim 8 (depends on 1)

The method of claim 1, wherein the subject has at least a one standard deviation increase in DepE score when compared to a normal subject that does not have a cognitive impairment.

### Claim 9

A method for selecting a treatment for improved cognition and/or prevention of cognitive dysfunction/loss by determining a depressive endophenotype (DepE) score comprising:
performing one or more tests on a subject to determine a depressive endophenotype (DepE), wherein the one or more tests comprise: feeling of worse memory problems, feeling downhearted and blue, feeling worthless, frequently feel like crying, and trouble concentrating; and
selecting a course of treatment for the subject based on whether the subject is scored as having a higher depressive endophenotype when compared to a normal subject that does not have cognitive dysfunction/loss, wherein the treatment is selected from at least one of: an antidepressant, a selective serotonin reuptake inhibitor, a selective serotonin 2C (5-HT2C) antagonist, a serotonin-norepinephrine reuptake inhibitor, or a tricyclic antidepressant.

### Claim 10 (depends on 9)

The method of claim 9, wherein a cognitive dysfunction is a disease or condition selected from Alzheimer's Disease, Parkinson's Disease, Down's syndrome, Frontotemporal dementia, Dementia with Lewy Bodies, Multiple sclerosis, traumatic brain injury, depression, schizophrenia, bipolar disease (and other mental illness), diabetes, hypertension, stroke, heart attack, dyslipidemia, other conditions/diseases or aging.

### Claim 11 (depends on 9)

The method of claim 9, wherein the DepE score is indicative for Alzheimer's Disease using a receiver operating characteristic (ROC) curve analysis.

### Claim 12 (depends on 9)

The method of claim 9, wherein a decrease in the DepE score is indicative of an improvement in at least one of: immediate memory scores and delayed memory scores.

### Claim 13 (depends on 9)

The method of claim 9, wherein the treatment is initiated before the subject is diagnosed with Alzheimer's Disease.

### Claim 14 (depends on 9)

The method of claim 9, wherein the subject has at least a one standard deviation increase in DepE score when compared to a normal subject that does not have a cognitive impairment.

### Claim 15

A method of determining if a drug treats a cognitive dysfunction, the method comprising:
(a) screening patients into a clinical trial based on tests for a depressive endophenotype (DepE);
(b) administering a candidate drug to a first subset of the patients, and a placebo to a second subset of the patients;
(c) determining if a DepE score predicts a treatment response such that a high depressive endophenotype group responded differentially than a low depressive endophenotype group;
(d) repeating step (a) after administration of the candidate drug or the placebo;
(e) determining if the candidate drug modifies the DepE score over a course of the trial; and
(f) determining if change in the DepE scores over the course of the trial has a positive response, a negative response, or a no treatment response, and if a statistically significant treatment response with the candidate drug is obtained for reducing or preventing the cognitive dysfunction.

### Claim 16 (depends on 15)

The method of claim 15, wherein the cognitive dysfunction is a disease or condition selected from Alzheimer's Disease, Parkinson's Disease, Down's syndrome, Frontotemporal dementia, Dementia with Lewy Bodies, Multiple Sclerosis, traumatic brain injury, depression, schizophrenia, bipolar disease (and other mental illness), diabetes, hypertension, stroke, heart attack, dyslipidemia, other conditions/diseases or aging.

### Claim 17 (depends on 15)

The method of claim 15, wherein an increase in the DepE score is indicative of an improvement in at least one of: immediate memory scores and delayed memory scores.

### Claim 18 (depends on 15)

The method of claim 15, wherein the tests for generating the DepE score comprise one or more of the following: feeling of worse memory problems, feeling downhearted and blue, feeling worthless, frequently feel like crying, and trouble concentrating to determine an elevation of the DepE score.

### Claim 19 (depends on 15)

The method of claim 15, wherein elevation of DepE score identifies those eligible for antidepressant therapy for improved cognition or prevention of cognitive loss.

### Claim 20

An apparatus for selecting a treatment for improved cognition as well as prevention of cognitive dysfunction/loss with a depressive endophenotype score comprising:
one or more tests for a subject indicative of the depressive endophenotype;
a processor that obtains an output from the one or more tests, wherein the depressive endophenotype score is calculated using learning machines (random forest, support vector machines), clustering algorithms (factor analysis, principal component analysis), summation of values, or other methods to generate the depressive endophenotype score from the one or more test; and
an output that indicates a course of treatment for the subject based on whether the subject is scored as having the depressive endophenotype, wherein the treatment is selected from at least one of: an antidepressant, a selective serotonin reuptake inhibitor, a selective serotonin 2C (5-HT2C) antagonist, a serotonin-norepinephrine reuptake inhibitor, or a tricyclic antidepressant.
